Patents Examined by Thomas J Visone
  • Patent number: 11123414
    Abstract: The present document describes a non-carcinogenic cream for delivery of active ingredients in the dermis of a patient, which comprises a synergistic combination of about 10 to 25% of oil about 10 to 25% of emulsifier about 1 to 12% of preservative about 45 to 80% of water, aloe water or hamamelis water; and about 1 to 25% of at least one homeopathic active ingredient chosen from pancreatinum, ruta graveolens, ledum palustre, colchicum autumnale, symphytum officinalis, salix alba, harpagophytum, bryonia, capsicum, rhododendron, benzoic acid, salicilicum acid, arnica montana, atropa belladonna, achillea millefolium, hamamelis, agaricus, aesculus, mercurius solubilis, mercurius iodatus, conium maculatum, echinacea angustifolia, echinacea purpurea, scrofularia nosada, pulsatilla, aconitum napellus, hypericum perforatum, bellis perennis, matricaria chamomilla, ranunculus, phytolacca decandra, dulcamara solanum, kalmia, actea racemosa, spigelia, gnaphalium, calendula officinalis, hepar sulphuris, somniferrum, ca
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: September 21, 2021
    Inventors: Samuel Glen, Barbara J. Johnston, Lynda Therrien Berthiaume, Molly Sharma
  • Patent number: 11096969
    Abstract: The present invention aims to provide a method which has not been established yet and which is useful for achieving long-term and fundamental cure of a necrotic cardiac tissue region to allow recovery of functionality of the heart. The present invention provides an injectable composition for treatment of a cardiac disease, the composition comprising fibroblasts, wherein the fibroblasts contain CD106-positive fibroblasts, preferably contain CD90-positive fibroblasts, and the fibroblasts do not form colonies.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: August 24, 2021
    Assignee: Metcela, Inc.
    Inventor: Takahiro Iwamiya
  • Patent number: 11061017
    Abstract: The invention relates to a method for high throughput screening compounds by using a plurality of automated cell based assays assessing skeletal muscle cells contractility, morphology, and metabolism, in order to predict the efficacy of said compound on a panel of applications linked with muscle physiological and pathophysiological processes, comprising: (i) providing an in vitro culture of myotubes, wherein the in vitro myotubes culture is obtained by the following method: providing a cell culture device allowing the culture of myoblasts or myotubes, depositing said cells from a human donor or human group of donors, in good health or affected by a muscle related disorder, from primary cells, a cell line, an isogenic cell line or differentiated stem cells recapitulating a muscle disorder, on said culture device by using a method allowing the spatial control of cell culture, culturing said cells during a determined incubation time so as to promote a spatially controlled myotube culture; (ii) adding at least on
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: July 13, 2021
    Assignee: CYTOO
    Inventors: Sebastien Degot, Yoran Margaron, Amelie Argento-Pucciarelli, Eve Duchemin-Pelletier, Joris Michaud, Mathieu Fernandes, Pauline Poydenot
  • Patent number: 11028385
    Abstract: The present invention relates to a formulation to stabilize lignocellulolytic enzyme mixture. This invention in particular relates to a formulation composed of lignocellulolytic enzyme with critical dosages of molasses either with petrochemical waste or glycerol as an additive to improve enzyme stability in a synergistic manner.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 8, 2021
    Assignees: Indian Oil Corporation Limited, Department of Biotechnology
    Inventors: Alok Satlewal, Ruchi Agrawal, Ravindra Kumar, Ravi Prakash Gupta, Suresh Kumar Puri, Sankara Sri Venkata Ramakumar
  • Patent number: 11028422
    Abstract: The present invention describes a process for preparing ultrapure (?95%) galacto-oligosaccharides (GOS), starting from GOS at lower purities by using sequential microbiological purifications involving Saccharomyces cerevisiae and Streptococcus thermophilus.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: June 8, 2021
    Assignee: Ritter Pharmaceuticals, Inc.
    Inventors: Silvia Giacomelli, Marco Manoni, Giovanni Cipolletti, Silvia Biagiolini, Luana Vagnoli, Jacopo Chini
  • Patent number: 11028454
    Abstract: The present application relates to methods for producing materials having viable micro-organisms incorporated therein. More particularly, the materials are produced under high temperature and/or high pressure conditions, and the micro-organisms are incorporated in the material before or during these conditions. Also provided are micro-organisms that remain viable under these conditions and have different applications, depending on the nature of the material.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: June 8, 2021
    Assignee: Resilux
    Inventors: Johan Mertens, Lynda Beladjal, Frank Devlieghere, Sam Verbrugghe, Benedikt Sas, Filip Du Prez, Tom Anthierens, Assia Ouchchen
  • Patent number: 11026409
    Abstract: The present invention in general relates to the field of biological crop protection by use of phytoseiid predatory mites. More particularly the present invention relates to a system for releasing a phytoseiid predatory mite in a crop and novel uses of host mites in such phytoseiid predatory mite releasing system. The phytoseiid predatory mite releasing system according to the invention and the uses according to the invention are characterised by the selection a host mite species having an intrinsic growth rate (rm) of <0.28.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 8, 2021
    Assignee: Koppert B.V.
    Inventors: Karel Jozef Florent Bolckmans, Yvonne Maria Van Houten, Adelmar Emmanuel Van Baal, Arno Theodoor Stam
  • Patent number: 11008546
    Abstract: The presently disclosed subject matter provides an approach to address the needs for microscale control in shaping the spacial geometry and microarchitecture of 3D collagen hydrogels. For example, the disclosed subject matter provides for compositions, methods, and systems employing N-sulfosuccinimidyl-6-(4?-azido-2?-nitro-phenylamino)hexanoate (“sulfo-SANPAH”), to prevent detachment of the hydrogel from the anchoring substrate due to cell-mediated contraction.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: May 18, 2021
    Inventors: Dongeun Huh, Mark Mondrinos, Cassidy Blundell, Jeongyun Seo
  • Patent number: 10980771
    Abstract: A protein crosslinker delivery device includes a body and a protein crosslinker held in a synthetic or natural biodegradable polymer. The body, a coating on the body, or an attachment to the body can contain the protein crosslinker holding biodegradable polymer. The release rate of the crosslinker and total amount of crosslinker released can be controlled by varying the concentration of the crosslinker and by varying the composition and structural characteristics of the degradable polymer. Surface eroding, bulk eroding and naturally occurring biodegradable polymers can be used in conjunction with a variety of nontoxic or minimally-toxic protein crosslinking agents. The devices can be used to treat mechanically damaged, deformed, and nutritionally deficient connective or soft tissues such as the knee meniscus, the spinal disc, the cornea, ligaments and tendons, the soft palate, and skin.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 20, 2021
    Assignee: Orthopeutics, L.P.
    Inventors: Pawel Slusarewicz, David A. Puleo, Thomas Paul Hedman, Sharath C. Sundararaj
  • Patent number: 10954276
    Abstract: The present invention is directed to enzyme based methods for removing water insoluble non-starch polysaccharides (NSPs) and/or water soluble or insoluble oligosaccharides from soy products without significantly damaging the proteins contained therein This removal is facilitated by the enzymatic hydrolysis of poly- and oligomeric carbohydrates into monosaccharides and other water soluble sugars. The present invention provides for the production of three streams of useful materials. The first is an enriched protein material comparable to the known SPCs but without significant quantities of undigestible oligosaccharides and polysaccharides. The second is an SPI made from the soluble protein in the hydrolysate which is valuable for high-quality feed, food and industrial uses. The third is the soluble saccharides and hydrolyzed carbohydrates (releasing sugars) that can be converted by fermentation to various valuable bioproducts.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: March 23, 2021
    Inventors: Lu-Kwang Ju, Abdullah Loman, Anthony Coffman, Qian Li, Srujana Koganti
  • Patent number: 10950348
    Abstract: A method is disclosed of predicting cancer patient response to immune checkpoint inhibitors, e.g., an antibody drug blocking ligand activation of programmed cell death 1 (PD-1) or CTLA4. The method includes obtaining mass spectrometry data from a blood-based sample of the patient, obtaining integrated intensity values in the mass spectrometry data of a multitude of pre-determined mass-spectral features; and operating on the mass spectral data with a programmed computer implementing a classifier. The classifier compares the integrated intensity values with feature values of a training set of class-labeled mass spectral data obtained from a multitude of melanoma patients with a classification algorithm and generates a class label for the sample. A class label “early” or the equivalent predicts the patient is likely to obtain relatively less benefit from the antibody drug and the class label “late” or the equivalent indicates the patient is likely to obtain relatively greater benefit from the antibody drug.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: March 16, 2021
    Assignee: BIODESIX, INC.
    Inventors: Joanna Röder, Krista Meyer, Julia Grigorieva, Maxim Tsypin, Carlos Oliveira, Arni Steingrimsson, Heinrich Röder, Senait Asmellash, Kevin Sayers, Caroline Maher
  • Patent number: 10940165
    Abstract: The present disclosure provides a composition comprising isolated T cells, wherein the T cells have specificity against a range of clinical fungal pathogens.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: March 9, 2021
    Assignees: The University of Sydney, Western Sydney Local Health District, Westmead Institute for Medical Research, NSW Health Pathology
    Inventors: David Gottlieb, Leighton Clancy, Emily Blyth, Kenneth Paul Micklethwaite, Shivashni Deo
  • Patent number: 10898612
    Abstract: An object of the present invention is to provide a cell structure which can be produced within a short period of time and has a predetermined or larger size, and a method for producing the above-described cell structure.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 26, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Kentaro Nakamura
  • Patent number: 10881060
    Abstract: The present invention relates to a method for identifying and/or characterising an endophyte strain, said method including providing a plurality of samples of endophytes, subjecting said endophytes to genetic analysis; subjecting said endophytes to metabolic analysis and selecting endophytes having a desired genetic and metabolic profile. The present invention also relates to novel endophytes having a desired toxin profile wherein the endophyte produces significantly less toxic alkaloids compared with a control endophyte such as standard toxic (ST) endophyte; and/or significantly more alkaloids conferring beneficial properties compared with a control endophyte such as ST endophyte. The present invention also relates to endophyte variants having a desired genetic and metabolic profile, wherein said endophyte variants possess genetic and/or metabolic characteristics that result in a beneficial phenotype in a plant harbouring or otherwise associated with the endophyte variant.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: January 5, 2021
    Assignee: Agriculture Victoria Services PTY LTD
    Inventors: German Spangenberg, Kathryn Michaela Guthridge, John White Forster, Timothy Ivor Sawbridge, Emma Jane Isobel Ludlow, Jatinder Kaur, Simone Jane Rochfort, Maia Andrea Rabinovich, Piyumi Ekanayake
  • Patent number: 10874701
    Abstract: The present invention provides a novel lactic acid bacterium having antioxidant and anti-aging functions and a dementia alleviation effect, and more specifically, provides Lactobacillus pentosus var. plantarum C29 KCCM11291P and Lactobacillus curvatus C3 KCCM430009. In addition, the present invention provides an antioxidant and anti-aging pharmaceutical composition and a dietary supplement containing the Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009 of the present invention as an active ingredient, and a composition for preventing or treating dementia and a dietary supplement for preventing or alleviating dementia, containing Lactobacillus pentosus var. plantarum C29 KCCM11291P or Lactobacillus curvatus C3 KCCM430009 as an active ingredient. Additionally, the present invention provides a composition for preventing or treating dementia, containing a fermentation composition, as an active ingredient, fermented by Lactobacillus pentosus var.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: December 29, 2020
    Inventors: Dong-Hyun Kim, Myung Joo Han, Il-Hoon Jung, Myung-Ah Jung
  • Patent number: 10842816
    Abstract: The technology described herein relates, at least in part, to compositions comprising and methods for isolating and enriching natural IgM-producing phagocytic B (NIMPAB) cells and methods of producing IgM antibodies using such cells, as well as uses of the antibodies produced by the methods for the prevention and treatment of diseases wherein immunotherapy with such natural IgM antibodies and their derivatives can be useful.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: November 24, 2020
    Assignees: Trustees of Boston University, Boston Medical Center Corporation
    Inventors: Xuemei Zhong, Joyce Wong
  • Patent number: 10828262
    Abstract: The present invention provides a method of preparing biomembrane, closed structure with biomembrane characteristics or cellular compartment, comprising the following steps: 1), acquire biological cells from natural tissues or natural biological species; 2), culture the cells obtained in step 1) massively in an appropriate environment; 3), acquire the lysates of cells in step 2), and extracting the biomembrane, closed structure with biomembrane characteristics and cellular compartment through differential centrifugation, density gradient centrifugation or dual-phase extraction individually or a combination of two methods or a combination of three methods thereof. The membrane is a natural biomembrane, closed structure with biomembrane characteristics and cellular compartment, which can be used for package of active ingredients in various fields.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: November 10, 2020
    Assignee: Hangzhou UMotor Biotech Co., LTD.
    Inventors: Ying Gao, Yanming Wang, Jianliang Wei, Minzi Wang, Ye Cheng, Mingzhou Zhang, Liying Ye
  • Patent number: 10780613
    Abstract: The present invention relates firstly to a method for reproducing a stem cell niche of an organism. The invention further relates to a reproduction of a stem cell niche of an organism. According to the invention, an image of a tissue of an organism is generated, which tissue comprises at least one stem cell niche. The image is filtered in order to obtain a structural pattern of the imaged stem cell niche. In a further step, a lithographic mask is generated from the structural pattern. According to the invention, a starting material of a substrate is structured by means of indirect or direct application of the lithographic mask, whereby a structured substrate is obtained which represents the reproduction of the imaged stem cell niche of the organism. The reproduction can be characterised as biolithomorphic.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: September 22, 2020
    Inventors: Andreas Schober, Joerg Hampl, Frank Weise, Justyna Borowiec, Uta Fernekorn, Michael Gebinoga, Sukhdeep Singh, Gregor Schlingloff, Sebastian Haefner, James Beck, Angelika Mueller, Astrid Voigt
  • Patent number: 10772917
    Abstract: Provided herein are therapies, and methods using that therapy, in the treatment of one or more of Type 2 diabetes (T2D), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subject may be candidates for treatment with one or more small molecule anti-diabetic drugs and the therapy may include implanting a population of pancreatic endocrine progenitor cells into the subject, where the cells are allowed to mature in vivo to produce a population.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 15, 2020
    Inventors: Timothy J. Kieffer, Jennifer E. Bruin
  • Patent number: 10765702
    Abstract: The invention provides methods for the treatment of vaginal laxity which include delivering a cell-containing composition to the vagina. The composition can include fat tissue to provide a bulking effect to reduce the size of the vaginal opening. The cells can provide healing and revascularization of the vaginal treatment area to sustain the bulking provided by the fat. The invention also provides systems and compositions useful for performing the method, and can include instruments and devices for removal of autologous adipose tissue from a patient (e.g., by liposuction), equipment for the enrichment of cells from adipose tissue, mechanical processing of adipose tissue, and the mixing of cells and processed adipose tissue. Devices for the delivery of the cell compositions to the vagina can also be included in the system.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 8, 2020
    Assignee: Boston Scientific Scimed, Inc.
    Inventor: David J. Yonce